21 results on '"Schetelig, Johannes"'
Search Results
2. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany.
- Author
-
Frietsch, Jochen J., Flossdorf, Sarah, Beck, James F., Kröger, Nicolaus, Fleischhauer, Katharina, Dreger, Peter, Schetelig, Johannes, Bornhäuser, Martin, Hochhaus, Andreas, and Hilgendorf, Inken
- Subjects
HEMATOPOIETIC stem cell transplantation ,YOUNG adults ,STEM cell transplantation ,ACHIEVED status ,OLDER patients - Abstract
Summary: Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998–2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event‐free and relapse‐free survival as well as for the cumulative incidences of non‐relapse and therapy‐related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post‐HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Post‐COVID‐19 condition in the German working population: A cross‐sectional study of 200,000 registered stem cell donors.
- Author
-
Bernas, Stefanie N., Baldauf, Henning, Real, Ruben, Sauter, Jürgen, Markert, Jan, Trost, Sarah, Tausche, Kristin, Behrends, Uta, Schmidt, Alexander H., and Schetelig, Johannes
- Subjects
STEM cell donors ,COVID-19 pandemic ,CROSS-sectional method ,BODY mass index - Abstract
Background: The SARS‐CoV‐2 pandemic has strained health systems worldwide, and infection numbers continue to rise. While previous data have already shown that many patients suffer from symptoms for months after an acute infection, data on risk factors and long‐term outcomes are incomplete, particularly for the working population. Objectives: We aimed to provide information on the prevalence of post‐COVID‐19 conditions in a subset of the German working‐age population (18–61 years old) and to analyze risk factors. Methods: We conducted an online survey with a health questionnaire among registered potential stem cell donors with or without a self‐reported history of polymerase chain reaction (PCR)‐confirmed SARS‐CoV‐2 infection. Logistic regression models were used to examine the risks of severity of acute infection, sex, age, body mass index, diabetes mellitus, and arterial hypertension medication on post‐COVID‐19 symptoms. Results: A total of 199,377 donors reported evaluable survey questionnaires—12,609 cases had a history of SARS‐CoV‐2 infection and 186,768 controls had none. Overall, cases reported physical, cognitive, and psychological complaints more frequently compared to controls. Increased rates of complaints persisted throughout 15 months postinfection, for example, 28.4%/19.3% of cases/controls reported fatigue (p <0.0001) and 9.5%/3.6% of cases/controls reported loss of concentration (p <0.0001). No significant differences were observed in the frequency of reported symptoms between 3 and 15 months postinfection. Multivariate analysis revealed a strong influence of the severity of the acute SARS‐CoV‐2 infection episode and age on the risk for post‐COVID‐19 conditions. Conclusion: We report the prevalence of post‐COVID‐19 conditions in mainly unvaccinated individuals with SARS‐CoV‐2 infections between February 2020 and August 2021. The severity of the acute course and age were major risk factors. Vaccinations may reduce the risk of post‐COVID‐19 conditions by reducing the risk of severe infections. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. P538: FAST‐TRACK MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION.
- Author
-
Roehnert, Maximilian, Kramer, Michael, Schadt, Jonas, Ensel, Philipp, Roellig, Christoph, Schetelig, Johannes, Stoelzel, Friedrich, Schlenk, Richard, Bornhaueser, Martin, von Bonin, Malte, and Oelschlaegel, Uta
- Published
- 2023
- Full Text
- View/download PDF
5. Anti‐CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.
- Author
-
Schetelig, Johannes, Link, Cornelia S., Stuhler, Gernot, Wagner, Eva M., Hänel, Mathias, Kobbe, Guido, Böttcher, Sebastian, Kreuzer, Karl‐Anton, Middeke, Jan M., Sockel, Katja, Teipel, Raphael, Bonin, Malte, Stölzel, Friedrich, Kramer, Michael, Stilgenbauer, Stephan, Hallek, Michael, and Bornhäuser, Martin
- Abstract
The article offers information on the chronic lymphocytic leukaemia (CLL) X4 trial which was conducted to harness the anti-CD20 antibody, ofatumumab, for disease-control peri-transplantation and prevention of chronic graft-versus-host disease (GVHD.) Topic discussed diagnosis of patients by flow cytometry of peripheral blood; treatment which comprised of induction therapy and observed that allogeneic Hematopoietic Cell Transplantation (alloHCT) had no significant impact on overall survival.
- Published
- 2019
- Full Text
- View/download PDF
6. P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA).
- Author
-
Sockel, Katja, Mütherig, Anke, Crysandt, Martina, Hänel, Mathias, Noppeney, Richard, Schaefer-Eckart, Kerstin, Kaufmann, Martin, Röllig, Christoph, Schetelig, Johannes, Zukunft, Sven, Fiebig, Frank, Giagounidis, Aristoteles, Scholl, Sebastian, Lück, Andreas, Rieger, Kathrin, Götze, Katharina, Geer, Thomas, Kiewe, Philipp, Müller-Tidow, Carsten, and Serve, Hubert
- Published
- 2023
- Full Text
- View/download PDF
7. The TP53 Pro72Arg SNP in <italic>de novo</italic> acute myeloid leukaemia – results of two cohort studies involving 215 patients and 3759 controls.
- Author
-
Schulz, Eduard, Lind, Karin, Renner, Wilfried, Petersen, Britt‐Sabina, Quehenberger, Franz, Dill, Claudia, Hofer, Sybille, Lal, Ridhima, Hoefler, Gerald, Schlenke, Peter, Ehninger, Gerhard, Schetelig, Johannes, Middeke, Jan M., Stölzel, Friedrich, and Sill, Heinz
- Subjects
P53 protein ,ACUTE myeloid leukemia ,MYELOID leukemia ,PATIENTS - Published
- 2018
- Full Text
- View/download PDF
8. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation ( EBMT).
- Author
-
Schetelig, Johannes, Wreede, Liesbeth C., Andersen, Niels S., Moreno, Carol, Gelder, Michel, Vitek, Antonin, Karas, Michal, Michallet, Mauricette, Machaczka, Maciej, Gramatzki, Martin, Beelen, Dietrich, Finke, Jürgen, Delgado, Julio, Volin, Liisa, Passweg, Jakob, Dreger, Peter, Schaap, Nicolaas, Wagner, Eva, Henseler, Anja, and Biezen, Anja
- Subjects
- *
HOMOGRAFTS , *CHRONIC lymphocytic leukemia , *STEM cell transplantation , *RETROSPECTIVE studies , *PROGRESSION-free survival , *CANCER risk factors - Abstract
The best approach for allogeneic haematopoietic stem cell transplantations (allo HCT) in patients with chronic lymphocytic leukaemia ( CLL) is unknown. We therefore analysed the impact of procedure- and centre-related factors on 5-year event-free survival ( EFS) in a large retrospective study. Data of 684 CLL patients who received a first allo HCT between 2000 and 2011 were analysed by multivariable Cox proportional hazards models with a frailty component to investigate unexplained centre heterogeneity. Five-year EFS of the whole cohort was 37% (95% confidence interval [ CI], 34-42%). Larger numbers of CLL allo HCTs (hazard ratio [ HR] 0·96, P = 0·002), certification of quality management ( HR 0·7, P = 0·045) and a higher gross national income per capita ( HR 0·4, P = 0·04) improved EFS. In vivo T-cell depletion ( TCD) with alemtuzumab compared to no TCD ( HR 1·5, P = 0·03), and a female donor compared to a male donor for a male patient ( HR 1·4, P = 0·02) had a negative impact on EFS, but not non-myeloablative versus more intensive conditioning. After correcting for patient-, procedure- and centre-characteristics, significant variation in centre outcomes persisted. In conclusion, further research on the impact of centre and procedural characteristics is warranted. Non-myeloablative conditioning appears to be the preferable approach for patients with CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
- Author
-
Onida, Francesco, Wreede, Liesbeth C., Biezen, Anja, Eikema, Diderik‐Jan, Byrne, Jenny L., Iori, Anna P., Schots, Rik, Jungova, Alexandra, Schetelig, Johannes, Finke, Jürgen, Veelken, Hendrik, Johansson, Jan‐Erik, Craddock, Charles, Stelljes, Matthias, Theobald, Matthias, Holler, Ernst, Schanz, Urs, Schaap, Nicolaas, Bittenbring, Jörg, and Olavarria, Eduardo
- Subjects
STEM cell transplantation ,TREATMENT of chronic myeloid leukemia ,HLA histocompatibility antigens ,CHRONIC leukemia ,HISTOCOMPATIBILITY class I antigens - Abstract
Atypical chronic myeloid leukaemia ( aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo- HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation ( EBMT) registry who underwent allo- HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen ( HLA)-identical siblings in 64% and matched unrelated ( MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo- HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality ( NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo- HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors.
- Author
-
Teipel, Raphael, Schetelig, Johannes, Kramer, Michael, Schmidt, Helmuth, Schmidt, Alexander H., Thiede, Christian, Oelschlägel, Uta, Kroschinsky, Frank, Bornhäuser, Martin, Ehninger, Gerhard, and Hölig, Kristina
- Subjects
- *
HEMATOPOIETIC stem cells , *GRANULOCYTE-colony stimulating factor , *BLOOD donors , *LEUKAPHERESIS , *LYMPHOCYTES , *ANTIGEN analysis , *BIOTHERAPY , *ORGAN donors , *PROBABILITY theory - Abstract
Background: The collection of hematopoietic stem cells from the peripheral blood of healthy donors has been established as a highly efficient method. Nevertheless, some donors have a moderate or poor chance of harvest success with standard mobilization regimens.Study Design and Methods: We retrospectively reviewed data from 7216 unrelated healthy donors, who underwent granulocyte-colony-stimulating factor mobilization and consecutive leukapheresis for allogeneic stem cell transplantation. We tested different donor variables of potential influence and established a statistical model for prediction of upfront mobilization capacity and harvest success. In addition, we calculated the likelihood of a successful harvest dependent on predicted preapheresis CD34+ count and recipient weight.Results: Female sex, older age, smoking, elevated lactate dehydrogenase, higher relative lymphocyte count, and higher large unstained cell count at baseline were negatively correlated with the CD34+ cell count on Day +5 (p < 0.0001). In contrast, higher platelet count, higher body mass index, higher absolute lymphocyte count, and higher relative monocyte count at baseline showed a positive correlation with the CD34+ count on Day +5 (p < 0.0001). Using a model built on these factors, we could significantly improve the prediction of harvest success compared to a basic model.Conclusion: The model allows the identification of female donors who eventually have a significant risk of harvest failure if requested to donate for recipients with a high body weight. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
11. Assessment of the T cell receptor repertoire in long‐term platelet donors by next generation sequencing.
- Author
-
Link, Cornelia S., Hölig, Kristina, Rücker‐Braun, Elke, Lang, Kathrin, Kuhn, Matthias, Eugster, Anne, Klesse, Christian, Schmiedgen, Maria, Heidenreich, Falk, Oelschlägel, Uta, Dahl, Andreas, Bornhäuser, Martin, Bonifacio, Ezio, and Schetelig, Johannes
- Subjects
T cell receptors ,BLOOD platelets - Published
- 2018
- Full Text
- View/download PDF
12. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
- Author
-
Österborg, Anders, Wierda, William G., Mayer, Jiří, Hess, Georg, Hillmen, Peter, Schetelig, Johannes, Schuh, Anna, Smolej, Lukáš, Beck, Christian, Dreyfus, Brigitte, Hellman, Andrzej, Kozlowski, Piotr, Pfreundschuh, Michael, Rizzi, Rita, Spacek, Martin, Phillips, Jennifer L., Gupta, Ira V., Williams, Vanessa, Jewell, Roxanne C., and Nebot, Noelia
- Subjects
CHRONIC lymphocytic leukemia treatment ,THERAPEUTIC use of monoclonal antibodies ,IMMUNOGLOBULIN G ,FLUDARABINE ,DRUG efficacy ,CD20 antigen ,PHARMACOKINETICS - Abstract
There are limited data on retreatment with monoclonal antibodies ( mAb) in patients with chronic lymphocytic leukaemia ( CLL). In a pivotal study, ofatumumab (human anti- CD20 mAb) monotherapy demonstrated a 47% objective response rate ( ORR) in fludarabine refractory CLL patients. From this study, a subset of 29 patients who had at least stable disease and then progressed were retreated with eight weekly ofatumumab infusions (induction treatment period), followed by monthly infusions for up to 2 years (maintenance treatment period). The ORR after 8 weeks of induction retreatment was 45% and 24% had continued disease control after maintenance at 52 weeks. Efficacy and safety of the retreated patients were compared with their initial results in the pivotal study. Response duration was 24·1 months vs. 6·8 months; time to next therapy was 14·8 months vs. 12·3 months; and progression-free survival was 7·4 months vs. 7·9 months (medians). Upon retreatment, 72% had infusion reactions, mostly Grade 1-2. Three patients had fatal infections. In summary, ofatumumab retreatment and maintenance therapy was feasible in patients with heavily pretreated CLL and appeared to result in more durable disease control than initial ofatumumab treatment in this subset of patients who may have a more favourable disease profile. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia.
- Author
-
Mohr, Brigitte, Schetelig, Johannes, Schäfer‐Eckart, Kerstin, Schmitz, Norbert, Hänel, Mathias, Rösler, Wolf, Frickhofen, Norbert, Link, Hartmut, Neubauer, Andreas, Schuler, Ulrich, Platzbecker, Uwe, Middeke, Jan M., Ehninger, Gerhard, Bornhäuser, Martin, Schaich, Markus, and Stölzel, Friedrich
- Subjects
- *
MYELOID leukemia , *LEUKEMIA treatment , *STEM cell transplantation , *CANCER chemotherapy , *CANCER patients , *CYTOGENETICS - Abstract
The role of allogeneic stem cell transplantation ( HSCT) as compared to chemotherapy in acute myeloid leukaemia ( AML) patients with abnormalities of chromosome 17p [abnl(17p)] has not yet been defined. Therefore, we analysed 3530 AML patients treated in three randomized, prospective, controlled clinical trials and compared post-remission therapies using a multivariate Cox regression analysis to determine whether allogeneic HSCT is superior than chemotherapy in overcoming the detrimental impact of patients with abnl(17p) AML. One hundred and forty-three patients (4%) were identified with abnl(17p) AML. All patients had received intensive induction chemotherapy. Forty-seven patients with a median age of 54 years (18-69 years) proceeded to allogeneic HSCT in first or second remission. The 3-year overall survival ( OS) rate for the entire cohort of patients was 4% [95% confidence interval ( CI), 1-7%]. OS and event-free survival at 3 years, calculated from the day of HSCT, was 11% (95% CI, 2-20%) and 6% (95% CI, 0-13%), respectively. Multivariate Cox regression analysis showed no benefit of allogeneic HSCT compared to chemotherapy (Hazard Ratio 0·97, 95% CI 0·56-1·67, P = 0·9). In conclusion, allogeneic HSCT does not improve survival in patients with abnl(17p) AML as compared to other adverse cytogenetic risk abnormalities. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
- Author
-
Lauter, Anett, Strumpf, Annette, Platzbecker, Uwe, Schetelig, Johannes, Wermke, Martin, Radke, Jörgen, Kiani, Alexander, Wunderlich, Gerd, Thiede, Christian, Ehninger, Gerhard, Kotzerke, Jorg, and Bornhäuser, Martin
- Subjects
RADIOTHERAPY ,MYELOID leukemia ,TRANSPLANTATION of organs, tissues, etc. ,T cells ,FLUDARABINE - Abstract
The addition of radioimmunotherapy to conventional and reduced-intensity conditioning has been shown to be feasible and effective. Within an ongoing prospective phase II trial, 22 patients with advanced myeloid malignancies and a median age of 65 years (range 54–76) received anti-CD66 Rhenium radioimmunotherapy followed by fludarabine (150 mg/m
2 ), busulfan (8 mg/kg) and alemtuzumab (75 mg) before allogeneic haematopoietic stem cell transplantation from matched sibling ( n = 7) and unrelated donors ( n = 15). The extramedullary toxicity in the first 100 d post-transplantation was limited and all patients engrafted with complete donor chimaerism. The incidence of non-relapse mortality at day 100 and after 2 years was 4·5% and 23%, respectively. The probability of overall survival at 2 years was 40%. A comparison with a younger historical cohort (median age 57 years) having received the same dose of fludarabine and busulfan but neither radioimmunotherapy nor alemtuzumab showed no difference in outcome. Although the use of alemtuzumab reduced the incidence of acute graft- versus-host-disease, it was associated with a relapse incidence of 40% despite the incorporation of radioimmmunotherapy. In summary, we confirmed the feasibility of combined radioimmunotherapy and reduced-intensity conditioning in elderly patients. Further optimisation, probably involving less T cell depletion, is necessary before a randomized comparison with standard conditioning can be planned. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
15. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
- Author
-
Schetelig, Johannes, Breitschaft, Astrid, Kröger, Nicolaus, Zabelina, Tatjana, Ebell, Wolfram, Bornhäuser, Martin, Haack, Astrid, Ehninger, Gerhard, Salama, Abdulgabar, and Siegert, Wolfgang
- Subjects
- *
HOMOGRAFTS , *CELL transplantation , *TRANSPLANTATION of organs, tissues, etc. , *HEMAGGLUTININ , *CELLULAR immunity , *ERYTHROCYTES , *BLOOD donors , *BLOOD groups - Abstract
Isohemagglutinins directed against the donor blood group frequently delay erythroid engraftment after major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation (HPCT). Graft-versus-host reactions are capable of accelerating the clearance of isohemagglutinins. Whether immunogenicity of the A- and B-antigen is important in this process is unknown. Data of 807 patients from three centers were screened for patients with major or bidirectionally ABO-mismatched donors. Clinical data and red blood cell (RBC) transfusion support were analyzed retrospectively. A total of 158 patients with major or bidirectionally mismatched donors were identified. After major mismatched HPCT, patients with anti-A directed against the donor blood group required RBC transfusion support for a median of 109 days (range, 0-324 days) compared to 21 days (range, 2-98 days) for patients with anti-B directed against donor blood group (log-rank test, p = 0.0001). Other risk factors associated with prolonged RBC transfusion support in univariate analysis were age (p = 0.024), cytomegalovirus infection (p = 0.016), hemolytic anemia (p = 0.027), and chronic bleeding disorders (p = 0.038). The independent influence of donor blood group and recipient age were confirmed in a multivariate analysis. These results indicate that the immunogenicity of the ABO antigen plays an important role for the kinetics of erythroid engraftment after ABO-mismatched HPCT. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
16. Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia.
- Author
-
Kreuzer, Karl-Anton, Schmidt, Christian Andreas, Schetelig, Johannes, Held, Thomas K., Thiede, Christian, Ehninger, Gerhard, and Siegert, Wolfgang
- Subjects
STEM cell transplantation ,MYELOID leukemia ,LEUKEMIA treatment ,GRAFT rejection - Abstract
Abstract: It is hypothesised that an effective graft-vs.-leukaemia reaction contributes substantially to the therapeutic effect of reduced intensity conditioning stem cell transplantation in chronic myeloid leukaemia. However, kinetic data on eradication of leukaemia cells and stem cell engraftement which could support this assumption are lacking . Thus, we investigated bcr/abl fusion transcripts and haematopoietic chimerism in 14 patients undergoing such a transplantation protocol. Ten of them obtained a complete molecular remission, and two patients achieved haematologic remissions but remained bcr/abl positive. Weekly determinations of bcr/abl transcript numbers by qualitative and quantitative polymerase chain reaction and donor chimerism revealed that 10 responders cleared bcr/abl positive cells from the peripheral blood within a median of 9 wk (range 3–22 wk). The close relation (P = 0.0075) between the firstoccurrence of graft-vs.-host disease and the complete clearance ofbcr/abl positive blood cells argues in favour of an effective graft-vs.-leukaemia reaction. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
17. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
- Author
-
Bornhäuser, Martin, Kiehl, Michael, Siegert, Wolfgang, Schetelig, Johannes, Hertenstein, Bernd, Martin, Hans, Schwerdtfeger, Rainer, Sayer, Herbert G., Runde, Volker, Kröger, Nikolaus, Theuser, Catrin, and Ehninger, Gerhard
- Subjects
LEUKEMIA ,HOMOGRAFTS ,CHROMOSOMES - Abstract
This retrospective study describes the outcome of patients with chronic myeloid leukaemia after allografting using dose-reduced conditioning with fludarabine and busulphan. Forty-four Philadelphia chromosome (Ph)-positive patients were transplanted in nine German centres; 26 patients were in chronic phase, 11 in accelerated phase and seven in blast crisis. Thirty-four patients achieved complete remission, with 18 alive and disease-free at a median follow-up of 562 d (range 244–922 d). Grade II–IV acute graft-versus-host disease (GVHD) incidence was 43%. Twenty patients died, 15 of causes unrelated to relapse. Risk factors predisposing to graft failure by univariate analysis were an unrelated donor (8/23 compared with a related donor 2/21, P = 0·07) and interferon therapy within 90 d of transplant (4/6 versus 3/17, P = 0·025). At the last follow-up, of 31 patients for whom molecular or cytogenetic data were available, 16 (52%) were polymerase chain reaction-negative, and seven (23%) were Ph-negative by fluorescent in situ hybridization. These findings demonstrate that dose-reduced conditioning with fludarabine and busulphan provides durable engraftment and a low rate of relapse. However, in this population, many of whom were not eligible for high-dose conditioning due to age, reduced performance status, previous complications or extensive pre-treatment, these data highlight the need for effective anti-infectious and GVHD prophylaxis. In addition, this study supports the discontinuation of interferon therapy at least 90 d before transplant. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
18. Infections with human herpesvirus 6 variant B delay platelet engraftment after allogeneic haematopoietic stem cell transplantation.
- Author
-
Radonić, Aleksandar, Oswald, Olivia, Thulke, Stefanie, Brockhaus, Nina, Nitsche, Andreas, Siegert, Wolfgang, and Schetelig, Johannes
- Subjects
HERPESVIRUS diseases ,STEM cell transplantation ,HEMATOPOIETIC stem cells ,HUMAN herpesvirus-6 ,CRYOPRESERVATION of organs, tissues, etc. ,POLYMERASE chain reaction - Abstract
The clinical significance of human herpesvirus (HHV-6) infections after allogeneic stem cell transplantation (SCT) remains controversial. We analysed cryoconserved plasma samples from 82 patients after allogeneic SCT by quantitative polymerase chain reaction for HHV-6 variants A and B. Platelet engraftment was delayed in patients with HHV-6B infections but not with HHV-6A infections detected before day +28. In multivariate analysis early HHV-6B infections and the type of conditioning were associated with platelet engraftment. In conclusion, the two variants of HHV-6 should be studied separately; early infections with HHV-6B may contribute to delayed platelet engraftment after allogeneic SCT. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
19. The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.
- Author
-
Schulz E, Lind K, Renner W, Petersen BS, Quehenberger F, Dill C, Hofer S, Lal R, Hoefler G, Schlenke P, Ehninger G, Schetelig J, Middeke JM, Stölzel F, and Sill H
- Subjects
- Amino Acid Substitution, Case-Control Studies, Female, Humans, Male, Genetic Predisposition to Disease, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Mutation, Missense, Polymorphism, Single Nucleotide, Tumor Suppressor Protein p53 genetics
- Published
- 2018
- Full Text
- View/download PDF
20. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
- Author
-
Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, and Schetelig J
- Subjects
- Adolescent, Adult, Aged, Chromosome Aberrations, DNA Mutational Analysis methods, DNA, Neoplasm genetics, Humans, Leukemia, Myeloid, Acute therapy, Middle Aged, Polymorphism, Single Nucleotide, Randomized Controlled Trials as Topic methods, Survival Analysis, Treatment Outcome, Young Adult, Genes, p53 genetics, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid, Acute genetics, Mutation
- Abstract
Treatment success in patients with acute myeloid leukaemia (AML) is heterogeneous. Cytogenetic and molecular alterations are strong prognostic factors, which have been used to individualize treatment. Here, we studied the impact of TP53 mutations on the outcome of AML patients with adverse cytogenetic risk treated with allogeneic haematopoietic stem cell transplantation (HSCT). Samples of 97 patients with AML and adverse-risk cytogenetics who had received a HSCT within three randomized trials were analysed. Complete sequencing of the TP53 coding region was performed using next generation sequencing. The median age was 51 years. Overall, TP53 mutations were found in 40 patients (41%). With a median follow up of 67 months, the three-year probabilities of overall survival (OS) and event-free survival for patients with TP53 wild type were 33% [95% confidence interval (CI), 21% to 45%] and 24% (95% CI, 13% to 35%) compared to 10% (95% CI, 0% to 19%) and 8% (95% CI, 0% to 16%) (P = 0·002 and P = 0·007) for those with mutated TP53, respectively. In multivariate analysis, the TP53-mutation status had a negative impact on OS (Hazard Ratio = 1·7; P = 0·066). Mutational analysis of TP53 might be an important additional tool to predict outcome after HSCT in patients with adverse karyotype AML., (© 2016 John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
21. 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
- Author
-
Lauter A, Strumpf A, Platzbecker U, Schetelig J, Wermke M, Radke J, Kiani A, Wunderlich G, Thiede C, Ehninger G, Kotzerke J, and Bornhäuser M
- Subjects
- Adult, Aged, Antigens, CD immunology, Antigens, Neoplasm immunology, Cell Adhesion Molecules immunology, Epidemiologic Methods, Erythrocyte Transfusion, Female, Graft Survival, Graft vs Host Disease etiology, Humans, Lymphocyte Depletion methods, Male, Middle Aged, Platelet Transfusion, Radioimmunotherapy adverse effects, Radioisotopes therapeutic use, Recurrence, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid, Acute radiotherapy, Radioimmunotherapy methods, Rhenium therapeutic use, Transplantation Conditioning methods
- Abstract
The addition of radioimmunotherapy to conventional and reduced-intensity conditioning has been shown to be feasible and effective. Within an ongoing prospective phase II trial, 22 patients with advanced myeloid malignancies and a median age of 65 years (range 54-76) received anti-CD66 Rhenium radioimmunotherapy followed by fludarabine (150 mg/m(2)), busulfan (8 mg/kg) and alemtuzumab (75 mg) before allogeneic haematopoietic stem cell transplantation from matched sibling (n = 7) and unrelated donors (n = 15). The extramedullary toxicity in the first 100 d post-transplantation was limited and all patients engrafted with complete donor chimaerism. The incidence of non-relapse mortality at day 100 and after 2 years was 4.5% and 23%, respectively. The probability of overall survival at 2 years was 40%. A comparison with a younger historical cohort (median age 57 years) having received the same dose of fludarabine and busulfan but neither radioimmunotherapy nor alemtuzumab showed no difference in outcome. Although the use of alemtuzumab reduced the incidence of acute graft-versus-host-disease, it was associated with a relapse incidence of 40% despite the incorporation of radioimmmunotherapy. In summary, we confirmed the feasibility of combined radioimmunotherapy and reduced-intensity conditioning in elderly patients. Further optimisation, probably involving less T cell depletion, is necessary before a randomized comparison with standard conditioning can be planned.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.